I sent too early. I did chemo from 1/2020-4/2020. Had 1cm metastatic lesion to left lung 10/2020. Had lesion...

Thank you for the complete picture - this is incredibly valuable information. Your journey shows both the challenges of metastatic UPS and your proactive approach to treatment, including participation in cutting-edge immunotherapy trials.

Your Treatment Timeline & Current Status

Let me make sure I understand:

• 2019: Primary tumor (5cm left breast) → surgery + radiation
• During radiation: 2cm recurrence
• 2020: 6 cycles epirubicin/ifosfamide → achieved remission
• Oct 2020: 1cm lung metastasis → surgically resected
• 2021: First neoantigen vaccine trial (5 peptides) at UCSD
• 2023: Second vaccine trial showing weak response (3 of 9 peptides)
• Now: In remission, considering whether to continue vaccination

The Vaccine Question: What the Science Tells Us

Your question about continuing vaccination is exactly the right one to ask. Here's what we know:

Neoantigen vaccines are designed to train your immune system to recognize tumor-specific mutations. The fact that you showed any response (even weak to 3 peptides) suggests your immune system can recognize some tumor antigens, but the clinical benefit of continuing with weak responses is uncertain.

Key considerations:

• These trials are still establishing which patients benefit most and optimal duration
• A "weak response" in immunological terms doesn't always predict clinical outcomes
• The cost-benefit analysis you're doing is appropriate and important

Strategies for Durable Remission

According to NCCN Guidelines and emerging evidence, here are evidence-based approaches:

1. Optimal Surveillance (Your Best Tool Right Now)

NCCN recommends for stage IV sarcoma in remission:

• Chest CT every 3-6 months (lungs are highest risk given your history)
• Primary site imaging of left chest wall
• Physical exam every 3-6 months

Why this matters: Early detection of oligometastatic disease (like your 2020 lung lesion) allows for surgical resection, which can lead to long-term survival in select patients.

2. Metabolic & Immune System Optimization

While not specifically in NCCN guidelines, emerging research suggests:

Exercise & Physical Activity:

• Moderate-intensity exercise may enhance immune surveillance
• Helps maintain lean body mass (important for treatment tolerance if needed)
• Consider: 150 minutes/week moderate activity if physically able

Nutrition Considerations:

• Anti-inflammatory diet patterns (Mediterranean-style)
• Adequate protein for immune function
• Consider consultation with oncology dietitian

Sleep & Stress Management:

• Quality sleep supports immune function
• Chronic stress can impair immune surveillance

3. Biomarker Monitoring (If Available)

Questions to ask your team:

• Circulating tumor DNA (ctDNA): Some centers are using this for early detection of recurrence before imaging shows disease
• Immune profiling: Given your vaccine trials, has your team characterized your baseline immune function?

4. The Vaccine Decision Framework

Questions to discuss with your UCSD trial team:

1. "What does 'weak response' mean for my clinical outcomes?"

   • Is there data correlating immunological response strength to recurrence-free survival?

2. "Is there evidence that continued vaccination after weak response improves outcomes?"

   • Or does the benefit plateau after initial priming?

3. "Are there ways to potentially boost my response?"

   • Combination approaches (vaccines + checkpoint inhibitors)?
   • Different adjuvants or delivery methods?

4. "What would you recommend if I were your family member?"

   • Given the cost and uncertain benefit

5. "If I stop now, could I restart if there's evidence of recurrence?"

   • Is the "priming" you've already done valuable even with a break?

5. Emerging Approaches to Consider

Checkpoint Inhibitors: The NCCN Guidelines note that for some sarcoma subtypes, immunotherapy with agents like nivolumab or pembrolizumab may have activity. UPS has shown variable responses. Questions for your team:

• "Has my tumor been tested for PD-L1 expression or tumor mutational burden (TMB)?"
• "Given my vaccine responses, would checkpoint inhibitor therapy make sense as maintenance?"
• "Are there trials combining vaccines with checkpoint inhibitors for UPS?"

Clinical Trials: You've already shown willingness to participate in trials - this is valuable! Consider:

• Maintenance therapy trials for sarcoma in remission
• Combination immunotherapy approaches
• Search ClinicalTrials.gov for "undifferentiated pleomorphic sarcoma" + "maintenance" or "adjuvant"

6. Integrative Oncology Approaches

While not replacing standard surveillance, some patients find benefit from:

• Acupuncture for treatment-related symptoms
• Mind-body practices (meditation, yoga) for stress reduction
• Supplements: Discuss with your oncologist (some may interfere with surveillance or future treatments)

What the Data Shows About Your Situation

Positive prognostic factors in your case:

• ✓ Achieved remission after metastatic disease
• ✓ Oligometastatic disease (single lung lesion) successfully resected
• ✓ Good response to chemotherapy
• ✓ Some immune response to neoantigens (shows immune system engagement)

Risk factors to acknowledge:

• Early recurrence during initial radiation
• Metastatic disease (though successfully treated)
• High-grade histology (UPS)

What research tells us: Patients with UPS who achieve complete remission after metastasectomy (like your lung resection) can have prolonged disease-free survival, especially with close surveillance.

My Recommendation for Your Next Steps

1. Schedule a comprehensive discussion with your oncology team covering:

• Risk-benefit analysis of continuing vaccination given weak response
• Whether there are biomarkers (ctDNA, immune markers) that could guide decisions
• Optimal surveillance schedule for YOUR specific risk profile
• Any new trials or approaches since your last vaccine trial

2. Get clear on your surveillance plan:

• Exact imaging schedule and types
• Symptoms that should prompt immediate evaluation
• How long intensive surveillance should continue

3. Consider a second opinion at a sarcoma center of excellence if you haven't recently:

• Dana-Farber, MD Anderson, Memorial Sloan Kettering, or Mayo Clinic
• Specifically about maintenance strategies for metastatic UPS in remission

4. Optimize what you CAN control:

• Physical fitness and nutrition
• Stress management
• Sleep quality
• Staying connected to your medical team

The Honest Answer About "Durable Remission"

Here's what we know from NCCN Guidelines and sarcoma research:

There is no proven "maintenance therapy" for soft tissue sarcoma in remission after metastatic disease. The standard of care is vigilant surveillance with the goal of detecting and treating any recurrence early when it's most manageable.

Your vaccine trials represent cutting-edge science, but we don't yet have long-term data proving they extend remission. The decision to continue should weigh:

• Financial burden (significant consideration)
• Quality of life impact (time, side effects)
• Strength of evidence for benefit in your specific situation
• Your personal values about pursuing every possible option vs. living fully now

Questions to Bring to Your Team

About the vaccines:

1. "Can you show me data on patients with similar weak responses - what were their outcomes?"
2. "Is there a 'minimum effective response' threshold below which continuation isn't recommended?"
3. "What's the biological rationale for continuing with weak responses?"

About surveillance: 4. "Given my history of lung metastasis, should I have chest CTs every 3 months indefinitely?" 5. "Are there any blood-based biomarkers we should be monitoring?" 6. "At what point would you consider me 'cured' vs. 'in long-term remission'?"

About future options: 7. "If I recur again, what would be the treatment approach?" 8. "Are there any trials I should be aware of for UPS in remission?" 9. "Should I be doing